#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
GLP-1 drugs and diabetic foot reports
A 2026 FAERS analysis found a lower proportional reporting signal for diabetic foot complications, but it did not measure patient incidence or prove protection.
MASH fibrosis treatment panel update
An expert panel maps how semaglutide and resmetirom may fit MASH care, while long-term outcomes and direct comparisons remain open.
Semaglutide plus exercise in rats
A four-week rat study found partly distinct metabolic effects from semaglutide and aerobic training, with no direct evidence for menopausal women.
Semaglutide neuropathy case report
A single case found improved corneal nerve measurements after semaglutide, while neuropathy symptoms and disability scores stayed unchanged.
Semaglutide carbon model: what it found
A UK model estimated slightly lower lifetime emissions in two obesity populations but higher emissions with established cardiovascular disease.
GLP-1 Drugs and Anesthesia Safety
A 2026 study compared anesthesia outcomes for lipoabdominoplasty patients taking semaglutide or tirzepatide against those who were not.
How Incretin Drugs Affect the Heart
A new review finds heart benefits from incretin drugs like tirzepatide and retatrutide involve pathways beyond blood sugar control.
Incretin Drugs and the Sarcopenia Question
A new review argues that incretin drugs such as tirzepatide and semaglutide need built-in muscle monitoring alongside fat-loss tracking.
Novo sues Lilly over GLP-1 ad claims
Novo Nordisk sued Eli Lilly over GLP-1 ads it says compare Zepbound with lower-dose Wegovy. Here is what the false-advertising suit alleges.
Semaglutide and Alzheimer's after EVOKE
Semaglutide failed both EVOKE Alzheimer's trials. A new paper argues research should shift from one hypothesis to a stratified program.
Tirzepatide and Oral Contraceptives
A new review asks whether tirzepatide's slowed digestion could also blunt oral progestogens used beyond birth control pills.
Tirzepatide vs GLP-1RAs and IBD risk
A US propensity-matched study found tirzepatide linked to fewer IV steroid courses than other GLP-1 drugs among patients who already have IBD.